MedImmune develops innovative, high-value biological products that improve health, enhance lives and help to make a world of difference. Flumist® Quadrivalent (Influenza Vaccine live, Intranasal), a MedImmune product, is the first and only nasal spray flu vaccine approved in the United States to help prevent influenza and is indicated for the active immunization of eligible individuals 2 to 49 years of age against influenza disease caused by influenza virus subtypes A and B contained in the vaccine.
In the world of biologics, MedImmune has established itself as a true visionary, with one of the most robust pipelines in the biopharmaceutical industry. From groundbreaking research and development, to state-of-the-art manufacturing, to product commercialization, MedImmune improves lives. Through the spirit of innovation, the heart of inspiration, and the strength of integration, MedImmune advances science for better health.
MPPG is pleased to offer discounts up to 20% on MedImmune products:
Flumist Quadrivalent (Influenza Vaccine Live, Intranasal)
In order to take advantage of the MPPG contract with Medimmune, a group affiliation declaration form is required. Flumist Purchasing Group Declaration
Flumist is only sold through distributors. Our MPPG partner McKesson/PSS will process your Flumist Quadrivalent orders. Download the FluMist Quadrivalent Order Form .
Find more information about Flumist Quadrivalent here.